October 19, 2016 5:21pm

 

… As financial reporting/earning’s nervousness begins 7 days from today

As I had stated on Tuesday, when the sector ran higher … “The daily trade has been very short-term trend and traders will get very ‘grabby” – so went Wednesday.

 

Pre-open indication’s tally:  4 hit (AST, ATHX, CLLS and ISCO) and 1 miss (BTX)

Out and about:  Organovo Holdings (ONVO) proposes offering while AGTC has filed an IND to conduct a P1/2 clinical trial for the treatment of achromatopsia caused by mutations in the CNGA3 gene and Sangamo Biosciences (SGMO) will release Q3 results on 10/26

 

I answer one question; in which company should investors put, keep and commit their money!

 

Do you care what happened today, you could have known … because it has implications to Thursday's sector activity?  

Subscribe or lose!

 

It's a daunting task to understand risk, seeing the unforeseen; on the basis of my own code of reliability, I have one rule: I eat my own cooking and I speak to my “concerns”! 

 

 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

 

Stocks closed mostly higher on Wednesday, helped by better-than-expected earnings and rising oil prices, following the release of key economic data from the Federal Reserve.

The NASDAQ closed UP +2.58 or +0.05% to 5,246.41 and the DOW closed UP +40.68 or +0.22% to 18,202.62.  

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was negative with an A/DL of 12/24 and 7 flats;
  • The mid-day stayed negative with an A/DL of 13/29 and 1 flat – the opposite of yesterday;
  • The closing bell  was negative with A/DL of 14/26 and 3 flats;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened negative, stayed negative at the mid-day and closed negative.

I keep telling investors in the a.m. to check the indexes:  

  • The iShares Russell 2000 (IWM) indicated a negative pre-open -0.02%, and was UP +0.42% at the close while the iShares Nasdaq Biotechnology (IBB) did NOT indicated in the pre-open  and closed DOWN -0.72%.

 

 

Lately, it is NOT about improving fundamentals that push stock prices lower but, the view of risk.

  • Wednesday closed NEGATIVE with 26 decliners, 14 advancers and 3 flats;
  • Tuesday closed POSITIVE with 12 decliners, 27 advancers and 2 flats;
  • Monday closed NEGATIVE with 34 decliners, 7 advancers and 2 flats;

 

 

Look close at today and the past days – trading ranges - I see patterns:

The downside trend reflects a pricing trend range of:

  • Wednesday’s decline ranged from -0.29 to -7.69% in twenty-seven (27) equities;
  • Tuesday’s decline from -0.24% to -6.58% in twelve (12) equities;
  • Monday’s decline ranged from –0.05% to –10.07%  in thirty-four (34) equities;
  • Friday’s decline ranged from -0.53% to -13.29% in twenty-nine (29) equities
  • Thursday’s decline ranged  from -0.23% to -5.95% in thirty-one (31) equities;
  • Last Wednesday decline ranged -0.73% to -8.89% in thirty-six (36) equities;

The upside shows a pricing trend range of:

  • Wednesday’s upside ranged from +0.24% to 14.34% in sixteen (16) equities;
  • Tuesday’s upside ranged from +0.24% to +11.24% in twenty-seven (27) equities;
  • Monday upside ranged from +0.12 to +4.66% in seven (7) equities
  • Friday’s upside ranged from +0.52% to +3.95% in twelve (12) equities;
  • Thursday’s upside ranged  from +0.12% to +3.84% in nine (9) equities;
  • Last Wednesday’s upside ranged +0.44% to +11.68% in six (6) equities;

 

Wrap-up: The day’s sector <43 companies> 16 gains declined from Tuesday’s 27 with decreasing volume;  while the downside of twenty-seven (27) compared to Tuesday’s twelve (12) also with decreased volume … as the number of downside companies increased by fourteen (14) as the sector’s risk tolerance was recognized  …

 

 

Pre-market indication review:  4 hit and 1 miss:

  • Asterias Biotherapeutics (NYSEMKT: AST) closed UP +$0.15 – hit;
  • Athersys (ATHX) closed UP +$0.00 – hit;
  • BioTime (NYSEMKT: BTX) closed DOWN -$0.05 – miss;
  • Cellectis SA (CLLS) closed UP +$0.00 – hit;
  • International Stem Cell (ISCO) closed DOWN -$0.05 – hit;

 

 

Out and about:

Organovo Holdings (ONVO) closed DOWN -$0.04 to $3.49 …

  • ONVO has commenced an underwritten public offering of its common stock.  The offering is subject to market and other conditions, and there is NO size and terms of the offering – at the moment;     
  • Jefferies LLC and Evercore ISI are acting as joint book-running managers for the offering. Raymond James & Associates, Inc. is acting as lead manager, and BTIG is acting as co-manager.

 

Applied Genetic Technologies Corporation (AGTC) closed FLAT at $8.70 …

  • AGTC has filed an IND with the U.S. FDA to conduct a P1/2 clinical trial for the treatment of achromatopsia caused by mutations in the CNGA3 gene;
  • Achromatopsia results from mutations in one of several genes. Two of these genes, CNGA3 and CNGB3, encode the alpha and beta subunits, respectively, of an ion channel that is essential for proper function of cone cells within the retina. About 75% of achromatopsia patients have mutations in one of these two genes; the remainder of cases results from mutations in one of several other genes.

 

Sangamo BioSciences (SGMO) closed DOWN -$0.30 to $3.60 …

  • SGMO will release its Q3/16 financial results after the market closes on Wednesday, October 26, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast.

 

 

Percentage decliners:

  • Sangamo (SGMO) -7.69%;
  • Kite Pharma (KITE) -7.53%;
  • Spark Therapeutics (ONCE) -4.67%;
  • Opexa (OPXA) -4.23% after Tuesday’s -6.58%;
  • Juno Therapeutics (JUNO) -4.22%

 

 

Percentage advancers:

  • ImmunoCellular (NYSEMKT:IMUC) +14.34% or +$0.0119 after Tuesday’s+4.36% or +$0.0035;
  • Fibrocell (FCSC) +5.23%;
  • Asterias Biotherapeutics (NYSEMKT: AST) +4.17%;
  • Cytori (CYTX) +3.14% after Tuesday’s +3.24%;
  • Mesoblast (MESO) +1.67%

 

 

Flat:                                                                                                      

  • Athersys (ATHX) at $2.01;
  • Applied Genetic Technologies (AGTC) at $8.70;
  • Cellectis SA  (CLLS) at $19.55;

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Wednesday closed near 14.3;
  • Tuesday traded near 15;
  • Monday traded near 16.5;
  • Friday traded near 15.7;
  • Thursday traded near 17  - a +7.31% increase;
  • Last Wednesday traded above 15.5;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.